Eli Lilly - Plainly Now

Two FDA Reports of Deaths Name Unapproved Weight-Loss Drug Retatrutide, but Cause Is Unverified

By Plainly Now News Desk Published October 13, 2026

The main entrance of the U.S. Food and Drug Administration's headquarters building in Silver Spring, Maryland, with the agency's name in white letters above the glass doors.

Two FDA adverse-event reports from July and September 2026 name unapproved retatrutide in the deaths of women aged 41 and 49; the cause is still unverified.

FDA approves breast cancer pill Inluriyo for use with Verzenio in ESR1-mutated disease

By Plainly Now News Desk Published September 19, 2026 Updated October 13, 2026

The main entrance of FDA Building 1 on the agency's White Oak campus in Silver Spring, Maryland, with the words Food and Drug Administration above the glass doors.

FDA approves imlunestrant (Inluriyo) plus abemaciclib (Verzenio) for ESR1-mutated, HER2-negative breast cancer after hormone therapy progression.

Medicare Offers Wegovy and Zepbound for $50 a Month — but Some Patients With FDA-Approved Conditions Are Excluded

By Plainly Now News Desk Published August 31, 2026 Updated October 13, 2026

Boxes of Wegovy (semaglutide) injection pens

Since July 1, 2026, Medicare has let some beneficiaries buy the weight-loss drugs Wegovy, Zepbound and Foundayo for a flat $50 a month, instead of list prices

FDA Approves Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes

By Plainly Now News Desk Published August 29, 2026 Updated October 13, 2026

A Mounjaro (tirzepatide) KwikPen injector, the Eli Lilly drug the FDA approved to reduce cardiovascular risk in type 2 diabetes.

The Food and Drug Administration on August 28, 2026, expanded the approved use of Mounjaro, Eli Lilly’s tirzepatide injection, to include lowering the risk of major